[Results after 3 to 5 years of treatment of 219 cases of Parkinson's syndrome treated by L-Dopa and an L-Dopa -decarboxylase inhibitor combination].
D000367:Age Factors; D000368:Aged; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D003072:Cognition Disorders / Q000139:chemically induced; D004359:Drug Therapy, Combination; D004361:Drug Tolerance; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use*; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced; D010302:Parkinson Disease, Secondary / Q000188:drug therapy*; D011379:Prognosis
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D007980:Levodopa
Résultats après trois à cinq ans de traitement de 219 cas de syndrome parkinsonien traité par la L-Dopa et l'association L-Dopa inhibiteur de la décarboxylase